Effexor XR Labeling Update Advises Of Increased Risk Of Fatal Outcomes Versus SSRIs
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth issues “Dear Healthcare Provider” letter advising that venlafaxine overdose may be associated with increased risk of fatal outcomes.
You may also be interested in...
FDA Says Effexor XR Ad Overstates Antidepressant’s Second-Line Utility
Wyeth no longer uses the journal ad targeted in warning letter, firm tells The Pink Sheet DAILY.
FDA Says Effexor XR Ad Overstates Antidepressant’s Second-Line Utility
Wyeth no longer uses the journal ad targeted in warning letter, firm tells The Pink Sheet DAILY.
Wyeth To Revisit Launch Plans For Effexor XR Follow-On
The company is waiting for results of lower dose desvenlafaxine studies, but says launch plans are not impacted by FDA's review extension.